Trial Profile
An Exploratory, Single Centre, Open Label, single and Multidose, Safety and Efficacy Study of the Treatment of Acute Decompensated Congestive Heart Failure with Vessel Dilator Peptide by Intravenous Infusion.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Atrial natriuretic factor (Primary)
- Indications Decompensated heart failure; Heart failure
- Focus Therapeutic Use
- Sponsors Madeleine Pharmaceuticals
- 23 Jul 2015 Status changed from active, no longer recruiting to completed as per Australian New Zealand Clinical Trials Registry record.
- 10 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by Australian New Zealand Clinical Trials Registry.
- 21 Jun 2012 Actual initiation date (Feb 2010) added and trial phase changed from II to I as reported by Australian New Zealand Clinical Trials Registry record.